OTLC Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 15:55):

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications...

Stats
Today's Volume	22 308.00
Average Volume	74 853.00
Market Cap	16.79M
EPS	$0 ( 2024-04-12 )
Next earnings date	( $0 ) 2024-05-17
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.10
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-29	Trieu Vuong	Buy	425 000	Common Stock
2023-06-28	Trieu Vuong	Buy	75 000	Common Stock
2023-06-16	Trieu Vuong	Buy	100 000	Common Stock
2023-06-14	Trieu Vuong	Buy	400 000	Common Stock
2023-05-26	Trieu Vuong	Buy	126 888	Common Stock

INSIDER POWER
100.00
Last 94 transactions
Buy: 129 604 070 \| Sell: 133 128 556

Oncotelic Therapeutics, Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Oncotelic Therapeutics, Financials

Annual	2023
Revenue:	$70 000.00
Gross Profit:	$70 000.00 (100.00 %)
EPS:	$-0.0199

FY	2023
Revenue:	$70 000.00
Gross Profit:	$70 000.00 (100.00 %)
EPS:	$-0.0199

FY	2022
Revenue:	$0
Gross Profit:	$-12 841.00 (0.00 %)
EPS:	$0.0464

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.0300

Financial Reports:

No articles found.

Oncotelic Therapeutics,

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.